US FDA has granted Sun Pharmaceutical Industries Ltd.’s subsidiary, two tentative approvals for its Abbreviated New Drug Applications (ANDA) for generic version of Januvia, Sitagliptin Tablets and generic version of Glumetza, Metformin HCl Extended-release tablets. Sitagliptin tablets, 25 mg, 50 mg, and 100 mg are therapeutic equivalents of Merck Sharp & Dohme Corporation’s Januvia tablets.

Sitagliptin tablets have annual sales of approximately USD 2.7 billion in the US. Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Metformin HCl Extended-release tablets, 500 mg and 1000 mg are therapeutic equivalents of Santarus Inc.’s Glumetza tablets. Metformin HCl Extended-release tablets have annual sales of approximately USD 140 million in the US. Metformin HCl Extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. – Medical Buyer Bureau


10 Diagnostic Imaging Trends for 2018

Video

 

Digital version